Core Viewpoint - The dispute over the ingredients in medical beauty products is escalating, particularly between Huaxi Biological and Juzhi Biological, with accusations of misleading information and legal threats being exchanged [1][5][6]. Group 1: Company Statements - Huaxi Biological issued a statement supporting Dr. Hao Yu, indicating that they had confirmed the authenticity of the testing reports and would cooperate with regulatory bodies if needed [2][3]. - Huaxi Biological accused Juzhi Biological of using online marketing tactics to undermine competition and suggested that they are prepared for a "real business war" [1][4]. - Juzhi Biological responded by stating that they would pursue legal action against those spreading false information and emphasized their commitment to consumer interests [1][5]. Group 2: Product Controversy - Dr. Hao Yu claimed that the product "Kefumei" from Juzhi Biological contained only 0.0177% of recombinant collagen, which does not meet regulatory standards for labeling as a non-trace component [3]. - Huaxi Biological highlighted that their products have the highest number of medical device certifications in the industry, asserting that there is no evidence to support the safety of recombinant collagen over hyaluronic acid [4]. Group 3: Financial Performance - Juzhi Biological reported significant revenue growth from 2022 to 2024, with revenues of 2.364 billion, 3.524 billion, and 5.539 billion yuan, and net profits of 1.002 billion, 1.452 billion, and 2.062 billion yuan respectively [6]. - In contrast, Huaxi Biological experienced a decline in both revenue and net profit for 2024, with revenues of approximately 5.371 billion yuan (down 11.61%) and net profits of about 174 million yuan (down 70.59%), marking their worst performance since going public [7]. Group 4: Market Reaction - Following the controversy, Juzhi Biological's stock price fell by 18.07% from its peak on May 20, closing at 68.25 HKD per share on June 2, reflecting market concerns over the ongoing disputes [6].